“The prolyl oligopeptidase inhibitor KYP‑2047 is not readily bioavailable to bloodstream form trypanosomes and human myelocytic leukemia cells” (2015) Journal of Pharmaceutical Negative Results, 6(1), pp. 7–10. Available at: https://mail.pnrjournal.com/index.php/home/article/view/84 (Accessed: 14 May 2026).